Study guide
15.4 The Normal Menstrual Cycle & Anticipatory Guidance
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
15.4 The Normal Menstrual Cycle & Anticipatory Guidance
Key Takeaways Explain This Topic AI
Normal cycles run 24 to 38 days with 8 or fewer days of flow and variation of 7 to 9 days or less between shortest and longest.
Adolescent cycles may be anovulatory for 1 to 2 years after menarche but should stay within 21 to 45 days and never exceed 90 days.
Premenstrual dysphoric disorder requires 5 or more symptoms with at least one core affective symptom, confirmed by prospective daily ratings across at least 2 cycles.
SSRIs are first-line for premenstrual dysphoric disorder and work within days, permitting luteal-phase-only dosing.
Menstrual toxic shock syndrome from TSST-1-producing Staphylococcus aureus presents with fever of 38.9 degrees Celsius or higher, diffuse macular erythroderma, hypotension, and later palmar desquamation, and a prior episode contraindicates tampons, cups, diaphragms, and cervical caps.
Last updated: September 2026
Everything that counts as abnormal bleeding is defined against what counts as normal, so the hypothalamic-pituitary-ovarian axis and the parameters of a normal cycle come first. This section also covers the anticipatory guidance the AMCB blueprint asks for by name: what to tell patients about menarche and adolescent cycles, how to distinguish premenstrual syndrome from premenstrual dysphoric disorder, and how to recognize and prevent menstrual toxic shock syndrome.
Normal Menstrual Cycle Neuroendocrinology
A regular menstrual cycle reflects the coordinated, reciprocal feedback loop of the Hypothalamic-Pituitary-Ovarian (HPO) axis acting directly on the uterine endometrium. Normal menstrual parameters in reproductive-age individuals encompass:
Cycle Frequency: 24 to 38 days (measured from the first day of menses to the first day of the subsequent menses).
Cycle Regularity: Variation between shortest and longest cycle of ≤7 to 9 days.
Bleeding Duration: ≤8 days of flow.
Volume of Blood Loss: Subjectively normal without causing anemia, flooding, or lifestyle disruption (historically quantified as 5 to 80 mL). Menstrual Cycle Regulatory Cascade
- ├── Hypothalamus ──> Pulsatile Gonadotropin-Releasing Hormone (GnRH)
- │ │ (Slow pulse frequency favors FSH; rapid favors LH)
- │ ▼
- ├── Anterior Pituitary ──> Follicle-Stimulating Hormone (FSH) & Luteinizing Hormone (LH)
- │ │
- │ ▼
- ├── Ovaries (Ovarian Cycle) ──> Folliculogenesis, Ovulation, & Corpus Luteum
- │ │ (Estradiol & Progesterone secretion)
- │ ▼
- └── Uterine Target (Endometrial Cycle) ──> Proliferative, Secretory, & Menstrual Phases
- 1. The Ovarian Cycle: Follicular vs. Luteal Phase
Follicular (Pre-ovulatory) Phase: Initiated on Day 1 of menses. Pulsatile GnRH stimulates the anterior pituitary to secrete FSH , which recruits a cohort of antral follicles. Ovarian granulosa cells aromatize theca-derived androgens into estradiol (E2) . As estradiol levels rise, FSH undergoes negative feedback inhibition, selecting a single dominant follicle (Graafian follicle) with the highest density of FSH receptors. The duration of the follicular phase is physiologically variable (typically 10 to 21 days) and accounts for normal menstrual cycle variability.
Ovulatory Mid-Cycle Surge: When sustained high circulating estradiol levels (>200 pg/mL for >48 hours) are attained by the mature dominant follicle, the feedback mechanism abruptly switches from negative to positive feedback , triggering the massive pituitary LH surge (with a smaller concurrent FSH surge). LH triggers resumption of oocyte meiosis, follicular rupture, and extrusion of the mature ovum approximately 24 to 36 hours after the onset of the surge (or 10 to 12 hours after the LH peak).
Luteal (Post-ovulatory) Phase: Following ovulation, the collapsed follicle luteinizes into the corpus luteum under the influence of LH. Luteinized granulosa and theca cells produce high concentrations of progesterone along with moderate estradiol. Progesterone exerts potent negative feedback on pituitary LH and FSH. Unlike the follicular phase, the luteal phase has a fixed, invariant lifespan of 14 ± 2 days . If conception and trophoblast hCG production do not occur, the corpus luteum undergoes programmed luteolysis into the fibrous corpus albicans, precipitating an acute withdrawal of progesterone and estradiol.
2. The Endometrial Cycle: Proliferative, Secretory, & Menstrual Phases
Proliferative Phase (Estrogen-Driven): Paralleling the ovarian follicular phase, rising estradiol induces rapid mitotic activity in the basal endometrial glands and stroma, regenerating the stratum functionalis from the surviving stratum basalis. Glands are initially straight, narrow, and tubular; the endometrial lining thickens from 1–2 mm up to 8–12 mm.
Secretory Phase (Progesterone-Driven): Paralleling the ovarian luteal phase, post-ovulatory progesterone halts endometrial cellular mitosis and initiates secretory differentiation. Glands become highly tortuous, coiled, and dilated, accumulating glycogen-rich vacuoles. Stromal cells undergo decidualization , and spiral arterioles elongate and coil tightly to supply the vascularized bed in preparation for blastocyst implantation.
Menstrual Phase (Progesterone Withdrawal): Luteolysis causes a precipitous drop in circulating progesterone and estradiol. Loss of hormonal support triggers intense, spasmodic constriction of the spiral arterioles , producing focal ischemia, hypoxia, and tissue necrosis of the stratum functionalis. Lysosomal enzymes release matrix metalloproteinases (MMPs), digesting the stromal extracellular matrix. Concurrently, local prostaglandins ( PGF2α and PGE2 ) stimulate rhythmic myometrial contractions to expel the necrotic decidual tissue and blood, while platelet plugs and local vasoconstrictors arrest bleeding in the basal vascular beds.
- Anticipatory Guidance Across the Menstrual Lifespan
- Menarche
Menarche occurs at a US median of about 12.4 years , with a normal range of roughly 8 to 15 years . Thelarche (breast budding) precedes it by about 2 to 2.5 years . ACOG treats the menstrual cycle as a vital sign in adolescents: cycles in the first 1 to 2 years after menarche are often anovulatory and irregular, but intervals should still fall within 21 to 45 days and never exceed 90 days . Evaluate no menses by age 15 with normal secondary sexual characteristics, or by age 13 with none.
Counsel adolescents and parents about what is normal (cycle length, flow duration, mittelschmerz, cyclic breast tenderness and mucus changes) and what is not (soaking a pad or tampon hourly, cycles more than 90 days apart, disabling dysmenorrhea that keeps her out of school).
Premenstrual Syndrome and Premenstrual Dysphoric Disorder
Cyclic mood and physical change in the luteal phase is normal ; the diagnosis is made by pattern, severity, and impairment — never by a single visit's recall.
PMS: physical and behavioral symptoms in the luteal phase that resolve within a few days of the onset of menses, with a symptom-free interval in the follicular phase .
PMDD (DSM-5-TR): at least 5 symptoms in the final week before menses, improving within a few days after onset and minimal in the week after, with at least one core affective symptom — marked lability, irritability or anger, depressed mood, or anxiety and tension — causing significant distress or impairment.
Diagnosis requires prospective daily ratings across at least 2 cycles (for example the Daily Record of Severity of Problems). Retrospective report misclassifies roughly half of self-diagnosed cases.
Treatment: SSRIs are first-line for PMDD and are unusual among antidepressant indications in that they work within days , which allows either continuous or luteal-phase-only dosing . Continuous combined oral contraception, particularly the drospirenone 3 mg with ethinyl estradiol 20 mcg 24/4 regimen, is FDA-approved. Add calcium 1,200 mg daily, aerobic exercise, and cognitive behavioral therapy. GnRH agonist with add-back therapy is reserved for refractory disease.
Menstrual Toxic Shock Syndrome
Toxic shock syndrome (TSS) is caused by TSST-1–producing Staphylococcus aureus and, in its menstrual form, is associated with high-absorbency tampons and with diaphragms, cervical caps, contraceptive sponges, and menstrual cups left in place too long.
Recognize it by the constellation: fever ≥38.9 °C , diffuse macular erythroderma ("sunburn" rash), hypotension with systolic ≤90 mmHg, desquamation of the palms and soles 1 to 2 weeks later , and involvement of three or more organ systems (vomiting or diarrhea, myalgia with creatine kinase at least twice normal, mucous membrane hyperemia, renal or hepatic derangement, platelets below 100,000, or disorientation).
Counsel every menstruating patient: use the lowest absorbency that works , change tampons every 4 to 8 hours , alternate with pads especially overnight, do not exceed the recommended wear time for a cup, and never leave a diaphragm in longer than 24 hours . Wash hands before insertion and removal. A prior episode of TSS is a contraindication to tampons, cups, diaphragms, and cervical caps.